ZYUS Life Sciences Receives No Objection Letter from Well being Canada for Proof-of-Idea Trial

SASKATOON, Saskatchewan — ZYUS Life Sciences Company (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences firm targeted on the event and commercialization of novel cannabinoid-based pharmaceutical drug candidates for ache administration, is happy to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has acquired a No Objection Letter (“NOL”) from Well being Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules.

Article content material

The NOL signifies Well being Canada’s settlement that the security info collected to this point concerning Trichomylin® softgel capsules helps progressing right into a affected person inhabitants. The POC trial goals to, amongst different issues, assess the preliminary efficacy and feasibility of Trichomylin® softgel capsules in sufferers with superior most cancers and reasonable to extreme cancer-related ache and derisk ZYUS’ beforehand introduced Part 2 medical trial.

About ZYUS Life Sciences Company

ZYUS (TSXV: ZYUS) is a life sciences firm targeted on the event and commercialization of novel cannabinoid-based pharmaceutical drug candidates for ache administration. Via rigorous scientific exploration and medical analysis, ZYUS goals to safe mental property safety, safeguarding its progressive therapies and bolstering shareholder worth. ZYUS’ unwavering dedication extends to acquiring regulatory approval of non-opioid-based pharmaceutical options, in pursuit of transformational influence on sufferers’ lives. For extra info, go to www.zyus.com or comply with us on X (previously generally known as Twitter) @ZYUSCorp.

Cautionary Be aware Relating to Ahead-Wanting Statements

This information launch incorporates “forward-looking information” throughout the which means of relevant securities legal guidelines referring to the Firm’s enterprise, the Firm’s potential to advance medical analysis actions, receive regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce merchandise that act as options to present ache administration therapies resembling opioids, and derisk the beforehand introduced Part 2 medical trial of Trichomylin^® softgel capsules. Any such forward-looking statements could also be recognized by phrases resembling “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans”, “will” and related expressions. Readers are cautioned to not place undue reliance on forward-looking statements. Statements about, amongst different issues, the Firm’s enterprise, the Firm’s potential to advance medical analysis actions, receive regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce merchandise that act as options to present ache administration therapies resembling opioids, and derisk the beforehand introduced Part 2 medical trial of Trichomylin^® softgel capsules are all forward-looking info. These statements shouldn’t be learn as ensures of future efficiency or outcomes. Such statements contain recognized and unknown dangers, uncertainties and different elements that will trigger precise outcomes, efficiency or achievements to be materially totally different from these implied by such statements. Though such statements are primarily based on administration’s affordable assumptions, there might be no assurance that the Firm will have the ability to obtain these outcomes. The Firm assumes no accountability to replace or revise forward-looking info to replicate new occasions or circumstances or precise outcomes except required by relevant regulation.

Neither the TSXV nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSXV) accepts accountability for the adequacy or accuracy of this press launch.

CT?id=bwnews&sty=20240730710496r1&sid=cnpm5&distro=ftp